Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,420 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01402687 | SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT) | completed | — | 181 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00871702 | Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease | completed | Phase 1 | 12 | Washington University School of MedicineOTHER | 1 | Jul 11, 2013 | clinicaltrials |
| NCT01440556 | Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma(MM2011) | completed | — | 196 | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | Jul 11, 2013 | clinicaltrials |
| NCT00085345 | Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 2 | 0 | OncotherapeuticsINDUSTRY | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00112879 | Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma | withdrawn | Phase 2 | 0 | The Cleveland ClinicOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT01371227 | A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 3 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Jul 4, 2013 | clinicaltrials |
| NCT00807677 | A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies | completed | Phase 1 | 31 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00609817 | Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma | terminated | Phase 1 | 9 | La Jolla Pharmaceutical CompanyINDUSTRY | 1 | Jun 25, 2013 | clinicaltrials |
| NCT00090493 | Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma | completed | Phase 2 / Phase 3 | 4 | University of ArkansasOTHER | 1 | Jun 24, 2013 | clinicaltrials |
| NCT01617213 | Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma(AMM-2011) | terminated | Phase 2 | 1 | University of VirginiaOTHER | 1 | Jun 21, 2013 | clinicaltrials |
| NCT01149668 | A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer | completed | Phase 1 | 7 | Pharmacyclics LLC.INDUSTRY | 1 | Jun 19, 2013 | clinicaltrials |
| NCT01868828 | A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma | unknown | Phase 4 | 50 | Peking University People's HospitalOTHER | 1 | Jun 6, 2013 | clinicaltrials |
| NCT01695590 | Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma | unknown | Phase 1 / Phase 2 | 40 | Prolexys PharmaceuticalsINDUSTRY | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00002556 | Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma | completed | Phase 3 | 312 | National Cancer Institute (NCI)NIH | 1 | May 31, 2013 | clinicaltrials |
| NCT01859234 | 89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma | unknown | N/A | 20 | University Medical Center GroningenOTHER | 1 | May 21, 2013 | clinicaltrials |
| NCT00054483 | Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction | completed | Phase 1 | 69 | National Cancer Institute (NCI)NIH | 1 | May 16, 2013 | clinicaltrials |
| NCT01801436 | A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma | completed | Phase 3 | 14 | Johnson & Johnson Taiwan LtdINDUSTRY | 0 | May 16, 2013 | clinicaltrials |
| NCT01292486 | Evaluation of the Spectra Optia® Mononuclear Cell Collection Procedure | completed | N/A | 32 | Terumo BCTINDUSTRY | 1 | May 1, 2013 | clinicaltrials |
| NCT00346255 | BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma(IMGN901) | completed | Phase 1 | 37 | ImmunoGen, Inc.INDUSTRY | 2 | Apr 23, 2013 | clinicaltrials |
| NCT00545519 | A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma | completed | Phase 1 | 6 | Washington University School of MedicineOTHER | 1 | Apr 23, 2013 | clinicaltrials |
| NCT01268774 | Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide. | completed | — | 529 | LEO PharmaINDUSTRY | 0 | Apr 18, 2013 | clinicaltrials |
| NCT00440635 | Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma | completed | — | 641 | Janssen-Cilag International NVINDUSTRY | 0 | Apr 16, 2013 | clinicaltrials |
| NCT01829412 | Whole Body Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) in Multiple Myeloma(MMY-MRI-08) | completed | N/A | 50 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 0 | Apr 11, 2013 | clinicaltrials |
| NCT00968396 | Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 5, 2013 | clinicaltrials |
| NCT01686386 | Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma | unknown | Phase 1 / Phase 2 | 60 | Gruppo Italiano Studio LinfomiOTHER | 1 | Apr 5, 2013 | clinicaltrials |
| NCT00060372 | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 27, 2013 | clinicaltrials |
| NCT00303797 | Sorafenib and Bortezomib in Treating Patients With Advanced Cancer | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2013 | clinicaltrials |
| NCT00996957 | Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 37 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAINDUSTRY | 1 | Mar 18, 2013 | clinicaltrials |
| NCT01179490 | Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma | terminated | Phase 2 | 5 | SymBio PharmaceuticalsINDUSTRY | 1 | Mar 18, 2013 | clinicaltrials |
| NCT01025206 | A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma | completed | Phase 1 | 35 | BioInvent International ABINDUSTRY | 4 | Mar 15, 2013 | clinicaltrials |
| NCT01148108 | Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma | completed | Phase 2 | 14 | TelikINDUSTRY | 1 | Mar 15, 2013 | clinicaltrials |
| NCT01536145 | CP-751,871 Treatment For Patients With Multiple Myeloma | completed | Phase 1 | 47 | PfizerINDUSTRY | 1 | Mar 15, 2013 | clinicaltrials |
| NCT01030302 | A Retreatment Study With Bortezomib for Multiple Myeloma | completed | — | 56 | Janssen Korea, Ltd., KoreaINDUSTRY | 0 | Mar 8, 2013 | clinicaltrials |
| NCT00661544 | Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients | completed | Phase 1 / Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2013 | clinicaltrials |
| NCT00536575 | Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 13 | SCRI Development Innovations, LLCOTHER | 1 | Feb 27, 2013 | clinicaltrials |
| NCT01396200 | Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine | completed | Early Phase 1 | 6 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 26, 2013 | clinicaltrials |
| NCT01005628 | Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS) | completed | — | 1,121 | Janssen Korea, Ltd., KoreaINDUSTRY | 1 | Feb 20, 2013 | clinicaltrials |
| NCT01680796 | Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | University of FloridaOTHER | 0 | Feb 20, 2013 | clinicaltrials |
| NCT01074060 | Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma | completed | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Feb 15, 2013 | clinicaltrials |
| NCT00428545 | Bevacizumab and Bortezomib in Patients With Advanced Malignancy | completed | Phase 1 | 104 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 12, 2013 | clinicaltrials |
| NCT00025415 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00310024 | Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00062621 | Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure | completed | Phase 1 | 5 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Feb 5, 2013 | clinicaltrials |
| NCT01780766 | Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI : Added Value of Diffusion Weighted Imaging | unknown | — | 100 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jan 31, 2013 | clinicaltrials |
| NCT01266811 | A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 3 | 0 | Centocor, Inc.INDUSTRY | 14 | Jan 28, 2013 | clinicaltrials |
| NCT00401804 | Bortezomib-Dexamethasone-Doxorubicin-Study | completed | Phase 2 | 72 | Austrian Forum Against CancerOTHER | 2 | Jan 24, 2013 | clinicaltrials |
| NCT00028821 | 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00047203 | Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00003166 | Bryostatin and Vincristine in B-Cell Malignancies | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Jan 11, 2013 | clinicaltrials |
| NCT01234974 | IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus | withdrawn | Phase 2 | 0 | Milton S. Hershey Medical CenterOTHER | 1 | Jan 10, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Jul 16, 2013source: clinicaltrials